6533b82dfe1ef96bd1290b5d

RESEARCH PRODUCT

Surplus protein myopathies.

Hans H. GoebelIrene Warlo

subject

Pathologymedicine.medical_specialtyMuscle Proteinsmacromolecular substancesMuscular DystrophiesNebulinNemaline myopathymedicineHumansMuscular dystrophyMyopathyNemaline bodiesMuscle SkeletalGenetics (clinical)ActinInclusion Bodiesbiologymedicine.diseaseMolecular biologyNeurologyPediatrics Perinatology and Child Healthbiology.proteinDesminNeurology (clinical)medicine.symptomSarcoglycanopathies

description

Abstract Certain muscular dystrophies are marked by absence or reduction of mutant proteins, foremost dystrophinopathies and sarcoglycanopathies. Conversely, other sporadic and familial neuromuscular conditions are marked by a surplus of proteins present in a granular or filamentous form, such as desmin-related myopathies, actinopathy and, perhaps, hyaline body myopathy. This emerging group of congenital myopathies is clinically, immunohistochemically, and genetically diverse. Clinically, early- and late-onset diseases with variable courses are described. Immunohistochemically, mutant gene-related and other proteins have been identified by immunohistochemistry. Mutations in the desmin and α -B crystallin genes have been discovered in desminopathies. Mutations in the actin gene, but in no other genes have been revealed in actinopathy. Surplus sarcoplasmic and/or intranuclear nemaline bodies have been related to mutant tropomyosin-3, actin and nebulin genes. This emerging concept of surplus protein myopathies will require substantial investigation to further interpret the results of present and future studies.

10.1016/s0960-8966(00)00165-6https://pubmed.ncbi.nlm.nih.gov/11166159